Rosemarie Truman -- Entrepreneur, Growth Strategist, Impact Investor, and Startup Catalyst -- Joins Ligandal as Advisor

By: Issuewire

Bethesda, Maryland Mar 2, 2021 ( - Ligandal is a venture-backed biotech company that seeks to cure genetic diseases using nanotechnology, predictively designed by supercomputing and artificial intelligence. Ligandal welcomes Rosemarie Truman to its Advisory Board. Rosemarie Truman is an entrepreneur, startup catalyst, impact investor, and former corporate executive. With over 25 years of experience in entrepreneurship, executive leadership, and philanthropy, Rosemarie's specialty is a venture investment strategy, having led growth strategies for 50 of the global Fortune 100 companies in over 15 countries.

Ms. Truman is the Founder and CEO of Ignite Social Impact, the first crowd-equity platform focused on "Tech-for-Good" social impact. Rosemarie also currently serves as Founder and CEO of the Center for Advancing Innovation (CAI), a 501c3 non-profit with a mission to identify breakthrough inventions and maximize their commercial potential through an award-winning, disruptive innovation platform. Prior to launching CAI, Rosemarie spearheaded IBM's innovation strategy practice globally and was awarded IBM's most laudable honor, the Golden Circle Award. She was the head of the strategy of the world's largest brokerage firm, Marsh & McLennan. In addition, she has also held leadership roles at Booz Allen Hamilton, Oracle, and PRTM. Rosemarie began her career at Goldman Sachs in investment banking, establishing a breakthrough straight-through processing platform for the New York Stock Exchange trading floor.

Ms. Truman said, "Ligandal has the team, business model, technology, and timing to be one of the world's leading genetic medicine companies. Most immediately, Ligandal's first-in-class antidote-vaccine to the SARS-CoV-2 coronavirus -- SARS-BLOCK -- has the potential to address the COVID-19 pandemic everywhere, not just in countries with cold supply chains. I'm delighted to join the Ligandal team and help them to make a positive impact around the world."

Andre Watson, Founder and CEO of Ligandal, added, "Rosemarie Truman is a real billionaire matchmaker, who creates and connects opportunities across entrepreneurial ecosystems unlike anyone else. With Rosemarie on our Advisory Board, Ligandal is better positioned to accelerate therapeutics and stop future pandemics."


Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Ligandal's current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. To date, Ligandal has raised more than $6M USD from leading funds and super angels to fund its innovative R&D programs.


The Center for Advancing Innovation (CAI) is a global public-private partnership, non-profit focused on creating a virtuous circle of innovation and driving growth breakthroughs through novel, creative paradigms and models. CAI's mission is to accelerate and increase the volume of technology commercialization to ignite entrepreneurship, bolster the global economy, and maximize the potential of promising inventions. CAI's award-winning challenge-based accelerator, rigorous evidence-based due diligence, and capital-efficient lean management models serve to hyper-accelerate "gazelle" high-performing startups for outsized investor returns. For additional information about CAI, please visit

Media Contact

Center for Advancing Innovation


9508 Burning Tree Rd

Source :Center for Advancing Innovation

This article was originally published by IssueWire. Read the original article here.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.